Abstract
Thromboembolic events contribute significantly to the morbidity and mortality in cancer. Effective and safe anticoagulation - mainstay in prevention and treatment of thrombosis - remains very challenging clinical task in oncology patients - population of high rate of treatment failure, bleeding complications and thromboembolic events recurrences. Prospective randomized clinical studies have documented that with advent of low molecular weight heparins new possibilities for thrombosis treatment and long-term prevention with more convenient and safe anticoagulation have emerged. Considerable advances have been achieved at present time in our understanding of the pathobiology of thrombogenesis in human malignancies, particularly of the interactions between coagulation cascade reactions and processes of tumor growth and dissemination. This builds up a new challenge for modern oncology - appreciation of the hypothesis of antimalignant effects of anticoagulants, which could influence the outcome of human cancer. Antineoplastic effects of antithrombotic drugs have been reported in various experimental models. Heparins have been the most extensively studied and have been shown to reduce the primary tumour growth and its metastatic spread. Joint evidence from fundamental research and from several randomized clinical trials, observing beneficial impact of low molecular weight heparins therapy on cancer patients survival, dictate the need for further scientific steps to confirm biological effects of heparins in human malignancies. The evidence is started to accumulate, that clinically approved heparins have different abilities to influence some processes of metastasis spread. The experimental work towards development of heparin derivates with low anticoagulant activity, but with potential inhibitory effects on tumor cells migration is in progress.
Keywords: Thromboembolism, cancer, metastatic spread, heparin, low molecular weight heparins
Anti-Cancer Agents in Medicinal Chemistry
Title: The Role of Anticoagulation in Cancer Patients: Facts and Figures
Volume: 6 Issue: 6
Author(s): Ferruccio De Lorenzo, Olena Dotsenko, Michael F. Scully and Myroslava Tymoshchuk
Affiliation:
Keywords: Thromboembolism, cancer, metastatic spread, heparin, low molecular weight heparins
Abstract: Thromboembolic events contribute significantly to the morbidity and mortality in cancer. Effective and safe anticoagulation - mainstay in prevention and treatment of thrombosis - remains very challenging clinical task in oncology patients - population of high rate of treatment failure, bleeding complications and thromboembolic events recurrences. Prospective randomized clinical studies have documented that with advent of low molecular weight heparins new possibilities for thrombosis treatment and long-term prevention with more convenient and safe anticoagulation have emerged. Considerable advances have been achieved at present time in our understanding of the pathobiology of thrombogenesis in human malignancies, particularly of the interactions between coagulation cascade reactions and processes of tumor growth and dissemination. This builds up a new challenge for modern oncology - appreciation of the hypothesis of antimalignant effects of anticoagulants, which could influence the outcome of human cancer. Antineoplastic effects of antithrombotic drugs have been reported in various experimental models. Heparins have been the most extensively studied and have been shown to reduce the primary tumour growth and its metastatic spread. Joint evidence from fundamental research and from several randomized clinical trials, observing beneficial impact of low molecular weight heparins therapy on cancer patients survival, dictate the need for further scientific steps to confirm biological effects of heparins in human malignancies. The evidence is started to accumulate, that clinically approved heparins have different abilities to influence some processes of metastasis spread. The experimental work towards development of heparin derivates with low anticoagulant activity, but with potential inhibitory effects on tumor cells migration is in progress.
Export Options
About this article
Cite this article as:
De Lorenzo Ferruccio, Dotsenko Olena, Scully F. Michael and Tymoshchuk Myroslava, The Role of Anticoagulation in Cancer Patients: Facts and Figures, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699112
DOI https://dx.doi.org/10.2174/187152006778699112 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Diagnostic Imaging of Fetal and Neonatal Abdominal and Soft Tissue Tumors
Current Pediatric Reviews Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Current Status of Pharmacological Thrombolytic Therapy and Mechanical Thrombectomy for the Treatment of Acute Deep Venous Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Adrenomedullin in Hypertension
Current Hypertension Reviews Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.
Current Vascular Pharmacology Preventing Vascular Graft Failure: Endothelial Cell Seeding and Tissue Engineering
Vascular Disease Prevention (Discontinued) Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Ascariasis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry